Western Wealth Management LLC Acquires 576 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Western Wealth Management LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,623 shares of the biopharmaceutical company’s stock after acquiring an additional 576 shares during the quarter. Western Wealth Management LLC’s holdings in Gilead Sciences were worth $699,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. PCA Investment Advisory Services Inc. bought a new stake in Gilead Sciences during the 2nd quarter valued at $25,000. OFI Invest Asset Management bought a new stake in Gilead Sciences during the 3rd quarter valued at $26,000. Tompkins Financial Corp raised its holdings in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares during the period. Fortitude Family Office LLC bought a new stake in Gilead Sciences during the 4th quarter valued at $29,000. Finally, Rakuten Securities Inc. bought a new position in shares of Gilead Sciences in the fourth quarter worth $33,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $66.76 on Friday. The company has a 50-day simple moving average of $71.96 and a two-hundred day simple moving average of $76.56. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a 12-month low of $65.90 and a 12-month high of $87.86. The firm has a market cap of $83.12 billion, a price-to-earnings ratio of 14.84, a PEG ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. During the same quarter in the previous year, the company earned $1.67 earnings per share. The business’s quarterly revenue was down 3.7% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 4.61%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio is presently 68.44%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on GILD shares. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a report on Friday. UBS Group decreased their price target on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a report on Wednesday. Royal Bank of Canada decreased their price target on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, February 14th. Cantor Fitzgerald decreased their price target on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Finally, Wells Fargo & Company decreased their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $84.71.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.